Legnaro National Laboratories, National Institute for Nuclear Physics, Legnaro, 35020 Padova, Italy.
Department of Environmental and Prevention Sciences, University of Ferrara, 44121 Ferrara, Italy.
Molecules. 2022 Feb 23;27(5):1501. doi: 10.3390/molecules27051501.
Is the Cu production worldwide feasible for expanding preclinical and clinical studies? How can we face the ingrowing demands of this emerging and promising theranostic radionuclide for personalized therapies? This review looks at the different production routes, including the accelerator- and reactor-based ones, providing a comprehensive overview of the actual Cu supply, with brief insight into its use in non-clinical and clinical studies. In addition to the most often explored nuclear reactions, this work focuses on the Cu separation and purification techniques, as well as the target material recovery procedures that are mandatory for the economic sustainability of the production cycle. The quality aspects, such as radiochemical, chemical, and radionuclidic purity, with particular attention to the coproduction of the counterpart Cu, are also taken into account, with detailed comparisons among the different production routes. Future possibilities related to new infrastructures are included in this work, as well as new developments on the radiopharmaceuticals aspects.
全球范围内的铜生产是否可行，以扩大临床前和临床研究？我们如何应对这种新兴的、有前途的治疗诊断放射性核素对个性化治疗的日益增长的需求？本文回顾了不同的生产途径，包括基于加速器和反应堆的途径，全面概述了实际的铜供应情况，并简要介绍了其在非临床和临床研究中的应用。除了最常探讨的核反应，本文还重点介绍了铜的分离和纯化技术，以及对于生产周期经济可持续性至关重要的靶材料回收程序。本文还考虑了质量方面，如放射化学、化学和放射性核素纯度，特别关注伴生铜的共生产，对不同生产途径进行了详细比较。本文还包括与新基础设施相关的未来可能性，以及放射性药物方面的新进展。
